Insulet Corporation (PODD) Fell Along with Broad Medtech Sector
ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here.
Insulet Corp (PODD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Zevenbergen Capital Investments Nancy Zevenbergen | 88,606 | $13,490,264 | -37% | 0.31% |
| 2. | Katamaran Capital Priya Kodeeswaran | 22,157 | $3,373,403 | 2.69% | |
| 3. | Ayrshire Capital Management John Nevin Jr. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $143.51 | 2,790 | $400,392.90 | 9,041 | 2026-06-03 | Filing | |
| $144.20 | 3,450 | $497,490.00 | 10,352 | 2026-06-03 | Filing | |
| $246.23 | 2,030 | $499,846.90 | 17,483 | 2026-02-25 | Filing | |
| $239.35 | 4,300 | $1,029,205.00 | 13,916 | 2026-02-20 | Filing | |
| $311.73 | 962 | $299,884.26 | 4,591 | 2025-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $143.27 | 418 | $59,886.86 | 4,329 | 2026-06-03 | Filing | |
| $293.09 | 1,851 | $542,509.59 | 2,158 | 2025-12-15 | Filing | |
| $347.49 | 687 | $238,725.63 | 3,456 | 2025-09-08 | Filing | |
| $348.81 | 797 | $278,001.57 | 3,890 | 2025-09-08 | Filing | |
| $332.23 | 4,263 | $1,416,296.49 | 16,736 | 2025-08-21 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 469,400 | $71,461,456 | 0.3% | |
| 2. | 337,747 | $51,421,981 | 0.55% | |
| 3. | 241,803 | $36,814,507 | 0.89% | |
| 4. | 177,819 | $27,072,943 | 0.07% | |
| 5. | 172,529 | $26,267,547 | 0.03% |
News See All
Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut?
TheFly reported on July 6 that Evercore ISI reduced its price target on PODD to $180 from $200 while maintaining an Outperform rating on the shares.
10 Best Innovative Healthcare Stocks to Buy Now
The U.S. healthcare sector has lagged behind the entire market for three consecutive years, with returns of just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
12 Best Stocks to Invest In According to Two Sigma Advisors with Huge Upside Potential
Two Sigma is one of the largest quantitative hedge funds in the world, with more than $70 billion in assets under management.
10 Stocks with Potential to Explode in 2026
On June 16, Reuters reported that Wells Fargo lifted the S&P 500 index target for year-end 2026 to 7,950 on the heels of healthier corporate earnings, reducing macroeconomic risks after the U.S.-Iran ...
10 Most Promising Healthcare Stocks According to Wall Street Analysts
The US healthcare sector has trailed the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
12 Best NASDAQ Stocks with High Upside Potential
On June 4, Hans Albrecht, Equity Fund Manager at Option Pit, joined BNN Bloomberg to discuss the outlook on the markets with a spotlight on tech.
Is Insulet Corporation (PODD) A Good Stock To Buy Now?
Is PODD a good stock to buy? We came across a bullish thesis on Insulet Corporation on The Wealth Dynasty Report’s Substack. In this article, we will summarize the bulls’ thesis on PODD.
8 Oversold Stocks to Buy Right Now
On June 1, Tom Lee, Fundstrat Managing Partner & Head of Research, and Fundstrat Capital CIO, appeared on CNBC's 'Squawk Box' to discuss the latest market trends.
Insulet Corporation (PODD) Initiates Voluntary Correction For Certain Omnipod Devices
Insulet Corporation (NASDAQ:PODD) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026.
Hedge Fund Resource Center